Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)
Imprime PGG, a yeast β-glucan immunomodulator, has the potential to repolarize human monocyte-derived M2 macrophages to M1 phenotype
Journal for ImmunoTherapy of Cancer volume 2, Article number: P191 (2014)
Background and objective
Imprime PGG (IPGG) has shown promising clinical efficacy in combination with monoclonal antibody treatment of cancer . In mice, complement receptor 3 (CR3) on innate immune cells (neutrophils and macrophages) is required for IPGG's anti-tumor activity [2, 3]. In human in vitro studies, opsonized IPGG binds CR3 on neutrophils and monocytes, but only on cells from individuals with high levels of endogenous anti-β-glucan antibodies (ABA), which is also a potential biomarker for enhanced clinical response to IPGG . Although IPGG has been shown to prime circulating neutrophils and monocytes, no data is available on its effect on N1/N2 neutrophil or M1/M2 macrophage tissue counterparts that can skew the immunostimulatory vs. immunosuppressive balance of the tumor microenvironment. The objective of this study was to investigate effects of IPGG treatment on monocyte differentiation to M1 or M2 macrophages.
Design and results
Monocytes enriched from IPGG- or vehicle-treated whole blood were cultured for six days in media containing GM-CSF or M-CSF to induce differentiation to M1 or M2 macrophages, respectively. Cells were then evaluated phenotypically for a panel of markers (including HLA-DR, CD163, CD206, CD209, CD80, CD86 and PD-L1) and functionally for the ability to drive CD4 T-cell proliferation and Th1 polarization. IPGG pretreatment did not affect M1 but did affect M2 as evidenced by down-modulation of CD163 and the ability of the cells to enhance CD4 T cell proliferation with a concomitant increase in interferon gamma production (Figures 1,2,3,). These changes were only observed in cells of individuals with high ABA levels.
IPGG has the potential to affect M2 to M1 repolarization and drive Th1 polarization. This engagement of the adaptive, along with the innate, immune system suggests that exploration of IPGG in combination with immunosuppression-relieving anti-cancer agents is warranted.
Bose N, Antonysamy MA, Patchen ML: Endogenous anti-β-glucan antibodies as a potential predictive biomarker for clinical response to Imprime PGG immunotherapy in non-small cell lung cancer (NSCSL) patients. J Clin Oncol. 2014, 32: 5s-10.1200/JCO.2013.49.4757. (suppl; abstr 3045)
Li B, Allendorf D, Hansen R: Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J Immunol. 2006, 177: 1661-1669. 10.4049/jimmunol.177.3.1661.
Qi C, Cai Y, Gunn L: Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived β-glucans. Blood. 2011, 117: 6825-6836. 10.1182/blood-2011-02-339812.
About this article
Cite this article
Chan, A.S., Qiu, X., Jonas, A.B. et al. Imprime PGG, a yeast β-glucan immunomodulator, has the potential to repolarize human monocyte-derived M2 macrophages to M1 phenotype. j. immunotherapy cancer 2 (Suppl 3), P191 (2014). https://doi.org/10.1186/2051-1426-2-S3-P191
- Tumor Microenvironment
- Interferon Gamma
- Innate Immune Cell
- Antibody Treatment